AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
DNA damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors
AACR Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment
Distinct mechanism of action of DNA damaging agent dianhydrogalactitol (VAL-083) suggests combination therapy with PARP inhibitors
SNO Pediatric Oncology Meeting
Dianhydrogalactitol (VAL-083) overcomes p53-mediated chemo-resistance and displays synergy with topoisomerase inhibitors
ASCO Annual Meeting 2017
Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma
WFNOS 2017
Clinical trials of VAL-083 in patients with chemoresistant glioblastoma
WFNOS 2017
Distinct mechanism of action of dianhydrogalactitol (VAL-083) overcomes chemoresistance in glioblastoma
AACR Annual Meeting 2017
Molecular Mechanisms of Dianhydrogalactitol (VAL-083) in Overcoming Chemoresistance in Glioblastoma
AACR Annual Meeting 2017
DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells
IASCL 17th World Congress on Lung Cancer
Assessment of Dianhydrogalactitol (VAL-083) in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemo-resistance